Moderna and Merck have announced what they describe as a "landmark" result from a Phase 3 clinical trial of their personalized mRNA cancer vaccine, intismeran autogene. The experimental therapy, which combines the vaccine with Merck's checkpoint inhibitor Keytruda, significantly reduced the recurrence and spread of high-risk melanoma in patients who had undergone surgery.

The trial, called INTerpath-001, met both its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS). The results showed that the combined therapy cut melanoma recurrence by nearly 50 percent compared to Keytruda alone.

The vaccine works by analyzing a patient's individual tumor and creating a customized mRNA treatment that teaches the immune system to recognize and attack cancer cells carrying specific mutations unique to that patient's tumor. The mRNA instructs cells to produce proteins that mimic tumor markers, effectively training the immune system to mount a targeted response against any remaining cancer.

"This is a landmark moment for personalized cancer treatment," researchers and company officials said. If the results hold up to regulatory review, intismeran autogene could become the first personalized mRNA cancer vaccine to receive full approval — building on the earlier emergency authorization of a similar approach for melanoma in some markets.

The significance extends beyond melanoma. If the approach works for other cancers, it could represent a paradigm shift in oncology: instead of one-size-fits-all chemotherapy, patients could receive a treatment literally designed around their individual tumor's genetic fingerprint. Moderna and Merck are reportedly exploring trials in other cancer types including lung, bladder, and colorectal cancers.

The trial enrolled patients with high-risk stage III or IV melanoma who had undergone complete surgical resection. The combined treatment was given as a series of injections alongside standard Keytruda infusions.

Sources